Rachel Carlson

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.

So Graham told me patent examiners may not always have access to all of the past research out there. And there are people who've argued some companies have gone too far by trying to patent things that they say shouldn't really be patented, like the way the room is set up while patients are getting treatment.

So Graham told me patent examiners may not always have access to all of the past research out there. And there are people who've argued some companies have gone too far by trying to patent things that they say shouldn't really be patented, like the way the room is set up while patients are getting treatment.

So Graham told me patent examiners may not always have access to all of the past research out there. And there are people who've argued some companies have gone too far by trying to patent things that they say shouldn't really be patented, like the way the room is set up while patients are getting treatment.

Yeah, exactly. And so it's still too early to say, but it's possible we could start to see more companies like Delix in the future. If investors are more inclined to put money into drugs that kind of work like psychedelics but don't involve actual psychedelics.

Yeah, exactly. And so it's still too early to say, but it's possible we could start to see more companies like Delix in the future. If investors are more inclined to put money into drugs that kind of work like psychedelics but don't involve actual psychedelics.

Yeah, exactly. And so it's still too early to say, but it's possible we could start to see more companies like Delix in the future. If investors are more inclined to put money into drugs that kind of work like psychedelics but don't involve actual psychedelics.

Yeah, some people definitely feel strongly that the whole experience that comes with these drugs is key when it comes to treating patients. Even David and Eliseo both told me they're not saying that we should replace psychedelics altogether with these non-hallucinogenic compounds. But they are saying that we should develop both things. Here's Eliseo.

Yeah, some people definitely feel strongly that the whole experience that comes with these drugs is key when it comes to treating patients. Even David and Eliseo both told me they're not saying that we should replace psychedelics altogether with these non-hallucinogenic compounds. But they are saying that we should develop both things. Here's Eliseo.

Yeah, some people definitely feel strongly that the whole experience that comes with these drugs is key when it comes to treating patients. Even David and Eliseo both told me they're not saying that we should replace psychedelics altogether with these non-hallucinogenic compounds. But they are saying that we should develop both things. Here's Eliseo.

Right. But again, not everyone feels like this is really the best way to approach the research. Remember Boris Heifetz? He's the anesthesiologist and neuroscientist at Stanford who did the ketamine study. We talked about it in our last episode. Yep. He and David are collaborators. And he told me that these new drugs, like the ones David's making, could be great.

Right. But again, not everyone feels like this is really the best way to approach the research. Remember Boris Heifetz? He's the anesthesiologist and neuroscientist at Stanford who did the ketamine study. We talked about it in our last episode. Yep. He and David are collaborators. And he told me that these new drugs, like the ones David's making, could be great.

Right. But again, not everyone feels like this is really the best way to approach the research. Remember Boris Heifetz? He's the anesthesiologist and neuroscientist at Stanford who did the ketamine study. We talked about it in our last episode. Yep. He and David are collaborators. And he told me that these new drugs, like the ones David's making, could be great.

But even then, if they do work, he still thinks these experiences people seem to have around psychedelics are really important. And for most patients, this whole idea of taking out the trip

But even then, if they do work, he still thinks these experiences people seem to have around psychedelics are really important. And for most patients, this whole idea of taking out the trip

But even then, if they do work, he still thinks these experiences people seem to have around psychedelics are really important. And for most patients, this whole idea of taking out the trip